GO
Loading...

Forest Laboratories Inc

More

  • NEW YORK, June 30- Most investments came up winners in the first half of 2014, which came to a close on Monday with solid gains for U.S. stocks, U.S. Treasuries, muni bonds, oil and gold. Forest Labs +64.9 Keurig Green +65.0.

  • WASHINGTON, June 30- Generic drugmaker Actavis Plc has won U.S. approval to buy specialty pharmaceuticals company Forest Laboratories on condition it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

  • FACTBOX-M&A frenzy transforming global pharma Tuesday, 6 May 2014 | 2:00 PM ET

    MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.

  • 'Superbug' war is on—and Washington wants a piece Wednesday, 30 Apr 2014 | 1:56 PM ET
    A magnified image of the MSRA bacteria. The "superbug" now kills 20,000 people each year.

    Two proposals in Congress are taking aim at deadly superbugs. But it's not exactly clear to some experts just what the right medicine should be.

  • Earlier this week, Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion for its experimental irritable bowel syndrome drug, the latest in several multi-billion dollar deals in the healthcare industry in the past week.

  • FACTBOX-M&A frenzy in healthcare sector Tuesday, 29 Apr 2014 | 2:25 PM ET

    **U.S. drugmaker Pfizer said on April 28 that it had offered to buy Britain's AstraZeneca Plc in January for about $98.9 billion, or nearly 47 pounds per share.

  • Early movers: MRK, COH, ADM, HLF & more Tuesday, 29 Apr 2014 | 7:46 AM ET
    Traders work on the floor of the New York Stock Exchange, April 16, 2014.

    Some of the names on the move ahead of the open.

  • Carl Icahn shakes value out of the underperforming Tuesday, 29 Apr 2014 | 7:00 AM ET

    Transforms reputation as corporate raider into shareholder activist by launching proxy fights to hold feet of under-performing boards to the fire.

  • *Pfizer works on next move in takeover bid for Astrazeneca. Leading the Nasdaq down was Amazon.com, which extended Friday's sharp drop a day after its earnings report. Shares of Pfizer gained 4.2 percent to $32.04 after the U.S. drugmaker was said to be working on its next move in a potential bid to take over Britain's AstraZeneca Plc.

  • *Pfizer works on next move in takeover bid for Astrazeneca. Leading the Nasdaq down was Amazon.com, which extended Friday's sharp decline a day after its earnings report.

  • Stocks rose on Monday, bouncing back after the prior session's drop, amid increased deal activity.

  • *Facebook and Amazon.com lead Nasdaq's losses. NEW YORK, April 28- The Nasdaq tumbled on Monday, led by a selloff in Facebook and Amazon.com, while the Dow clung to a slim gain in spite of Bank of America's suspension of a planned dividend increase. Amazon.com lost 3.1 percent to $294.74, extending Friday's sharp decline a day after its earnings report.

  • *To pay $95/ share in cash, $30/ share in milestone payment. April 28- Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments, to add a promising treatment for irritable bowel syndrome to its gastrointestinal drugs portfolio.

  • *Forest Labs to buy Furiex for up to $1.46 bln. Separately, Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion, including milestone payments to access Furiex's promising treatment for irritable bowel syndrome.

  • *Forest Labs to buy Furiex for up to $1.46 bln.

  • STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.

  • *Forest Labs to buy Furiex for up to $1.46 bln. *U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion bid to take over Britain's AstraZeneca Plc after two earlier bids were rejected.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Forest Labs to buy Furiex Pharma for up to $1.46 bln Monday, 28 Apr 2014 | 7:38 AM ET

    April 28- Forest Laboratories Inc said it would buy Furiex Pharmaceuticals Inc for up to $1.46 billion including milestone payments to access Furiex's treatment for irritable bowel syndrome. Forest, which itself is being acquired by Actavis Plc, said Actavis supported the deal announced on Monday.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.